EP1421203A4 - NEW ANTIGEN-BINDING MOLECULES FOR THERAPEUTIC, DIAGNOSTIC, PROPHYLACTIC, ENZYMATIC, INDUSTRIAL AND AGRICULTURAL APPLICATIONS AND METHOD FOR THE PRODUCTION AND SCREENING THEREOF - Google Patents

NEW ANTIGEN-BINDING MOLECULES FOR THERAPEUTIC, DIAGNOSTIC, PROPHYLACTIC, ENZYMATIC, INDUSTRIAL AND AGRICULTURAL APPLICATIONS AND METHOD FOR THE PRODUCTION AND SCREENING THEREOF

Info

Publication number
EP1421203A4
EP1421203A4 EP02747843A EP02747843A EP1421203A4 EP 1421203 A4 EP1421203 A4 EP 1421203A4 EP 02747843 A EP02747843 A EP 02747843A EP 02747843 A EP02747843 A EP 02747843A EP 1421203 A4 EP1421203 A4 EP 1421203A4
Authority
EP
European Patent Office
Prior art keywords
prophylactic
enzymatic
diagnostic
screening
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02747843A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1421203A2 (en
Inventor
Jay M Short
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Enzymes LLC
Original Assignee
Diversa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diversa Corp filed Critical Diversa Corp
Publication of EP1421203A2 publication Critical patent/EP1421203A2/en
Publication of EP1421203A4 publication Critical patent/EP1421203A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1027—Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP02747843A 2001-05-17 2002-05-17 NEW ANTIGEN-BINDING MOLECULES FOR THERAPEUTIC, DIAGNOSTIC, PROPHYLACTIC, ENZYMATIC, INDUSTRIAL AND AGRICULTURAL APPLICATIONS AND METHOD FOR THE PRODUCTION AND SCREENING THEREOF Withdrawn EP1421203A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30038101P 2001-05-17 2001-05-17
US300381P 2001-05-17
US30090701P 2001-06-25 2001-06-25
US300907P 2001-06-25
PCT/US2002/015767 WO2002092780A2 (en) 2001-05-17 2002-05-17 Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof

Publications (2)

Publication Number Publication Date
EP1421203A2 EP1421203A2 (en) 2004-05-26
EP1421203A4 true EP1421203A4 (en) 2005-06-01

Family

ID=26971759

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02747843A Withdrawn EP1421203A4 (en) 2001-05-17 2002-05-17 NEW ANTIGEN-BINDING MOLECULES FOR THERAPEUTIC, DIAGNOSTIC, PROPHYLACTIC, ENZYMATIC, INDUSTRIAL AND AGRICULTURAL APPLICATIONS AND METHOD FOR THE PRODUCTION AND SCREENING THEREOF

Country Status (3)

Country Link
EP (1) EP1421203A4 (enrdf_load_stackoverflow)
JP (1) JP2004532038A (enrdf_load_stackoverflow)
WO (1) WO2002092780A2 (enrdf_load_stackoverflow)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4975324B2 (ja) * 2002-11-09 2012-07-11 イムノコア リミテッド Ｔ細胞レセプターディスプレイ
ZA200604620B (en) 2003-12-10 2007-10-31 Medarex Inc IP-10 antibodies and their uses
EP2418220B1 (en) 2003-12-10 2017-08-02 E. R. Squibb & Sons, L.L.C. Interferon alpha antibodies and their uses
CN102863532A (zh) 2004-06-21 2013-01-09 米德列斯公司 干扰素α受体1抗体及其用途
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
EP1899379B1 (en) 2005-06-20 2018-04-11 E. R. Squibb & Sons, L.L.C. Cd19 antibodies and their uses
SG163554A1 (en) 2005-07-01 2010-08-30 Medarex Inc Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
MY144906A (en) 2005-10-21 2011-11-30 Novartis Ag Human antibodies against il13 and therapeutic uses
JP5512128B2 (ja) 2005-12-08 2014-06-04 メダレックス・リミテッド・ライアビリティ・カンパニー フコシルｇｍ１に対するヒトモノクローナル抗体および抗フコシルｇｍ１を使用するための方法
US8278421B2 (en) 2006-03-20 2012-10-02 Xoma Techolology Ltd. Human antibodies specific for gastrin materials and methods
BRPI0715332A2 (pt) 2006-08-04 2013-10-08 Novartis Ag Anticorpo, métodos de triar um anticorpo quanto ao domínio extracelular de uma proteína ephb3 útil para o tratamento de câncer, de alterar sistemicamente os anticorpos e triar um anticorpo quanto ao domínio extracelular de uma proteína ephb3 para o tratamento de câncer, de tratar um paciente que sofre de câncer, de alvejar uma célula tumoral que expressa epbh3, e de usar a célula hospedeira, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, composição farmacêutica, e kit.
TW200817437A (en) 2006-08-11 2008-04-16 Medarex Inc Monoclonal antibodies against stromal cell derived factor-1 (SDF-1)
EP2423231A3 (en) 2006-08-18 2012-05-30 Novartis AG PRLR-specific antibody and uses thereof
JP2010502220A (ja) 2006-09-05 2010-01-28 メダレックス インコーポレーティッド 骨形態形成タンパク質およびその受容体に対する抗体ならびにその使用方法
CN103897058B (zh) 2006-10-02 2018-06-15 E.R.施贵宝&圣斯有限责任公司 结合cxcr4的人类抗体及其用途
DK2068922T3 (da) 2006-10-19 2012-10-08 Csl Ltd Anti-IL-13Ralfa1-antistoffer samt deres anvendelser
US8618248B2 (en) 2006-10-31 2013-12-31 President And Fellows Of Harvard College Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
TW200837081A (en) 2006-11-15 2008-09-16 Medarex Inc Human monoclonal antibodies to BTLA and methods of use
KR101552735B1 (ko) 2006-12-01 2015-09-14 메다렉스, 엘.엘.시. 씨디22에 결합하는 인간 항체 및 이의 용도
EP2494988B1 (en) 2006-12-07 2015-09-30 Novartis AG Antagonist antibodies against EPHB3
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
WO2008074004A2 (en) 2006-12-14 2008-06-19 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
TR201904866T4 (tr) 2007-09-04 2019-04-22 Compugen Ltd Polipeptidler ve polinükleotidler ve bunların ilaç ve biyolojik madde üretmek için bir ilaç hedefi olarak kullanımları.
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
WO2009056634A2 (en) 2007-11-02 2009-05-07 Novartis Ag Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6)
AU2008337517B2 (en) 2007-12-14 2014-06-26 Novo Nordisk A/S Antibodies against human NKG2D and uses thereof
RU2528736C2 (ru) 2008-02-05 2014-09-20 Бристоль-Мейерз Сквибб Компани Антитела против альфа5-бета 1 и их применение
JP5504587B2 (ja) * 2008-05-27 2014-05-28 東レ株式会社 分析用チップ
CA2732782C (en) 2008-08-05 2019-02-26 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US20110311450A1 (en) 2008-12-08 2011-12-22 Zurit Levine Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
US8420084B2 (en) 2009-03-05 2013-04-16 Medarex, Inc. Fully human antibodies specific to CADM1
US9181339B2 (en) 2009-04-20 2015-11-10 Oxford Bio Therapeutics Ltd. Antibodies specific to cadherin-17
DK2424895T3 (en) 2009-04-27 2017-12-18 Novartis Ag Compositions and Methods for Increasing Muscle Growth
MX2011011338A (es) 2009-04-27 2012-04-19 Novartis Ag Composiciones y metodos de uso para anticuerpos terapeuticos especificos para la subunidad beta1 del receptor de il-12.
EP2454376B1 (en) * 2009-07-17 2015-12-02 Bioatla, LLC Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
WO2011021146A1 (en) 2009-08-20 2011-02-24 Pfizer Inc. Osteopontin antibodies
CN102597775A (zh) 2009-09-25 2012-07-18 佐马技术有限公司 筛选方法
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
EP2470569A1 (en) 2009-10-13 2012-07-04 Oxford Biotherapeutics Ltd. Antibodies against epha10
US9428586B2 (en) 2009-12-01 2016-08-30 Compugen Ltd Heparanase splice variant
CA2794483C (en) 2010-03-26 2020-07-07 Trustees Of Dartmouth College Vista regulatory t cell mediator protein, vista binding agents and use thereof
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
ES2949159T3 (es) 2010-05-06 2023-09-26 Novartis Ag Composiciones y métodos de uso para anticuerpos terapéuticos de proteína 6 relacionada con lipoproteínas de baja densidad (LRP6)
BR112012028326A2 (pt) 2010-05-06 2017-03-21 Novartis Ag anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos
US20130189268A1 (en) 2010-06-22 2013-07-25 Precision Biologics, Inc. Colon and pancreas cancer specific antigens and antibodies
CA2804746C (en) * 2010-07-16 2022-01-11 Jay M. Short Novel methods of protein evolution
US8557248B2 (en) 2010-08-09 2013-10-15 Cyvax, Inc. Methods and compositions for treating malaria
NZ607337A (en) 2010-08-20 2015-06-26 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
US8999335B2 (en) 2010-09-17 2015-04-07 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
CA3182320A1 (en) 2010-09-23 2012-03-29 Precision Biologics, Inc. Colon and pancreas cancer peptidomimetics
JP2013543384A (ja) 2010-10-05 2013-12-05 ノバルティス アーゲー 抗−ｉｌ１２ｒベータ１抗体ならびに自己免疫性および炎症性疾患の処置おけるその使用
EP2658971A1 (en) 2010-12-28 2013-11-06 XOMA Technology Ltd. Cell surface display using pdz domains
CN103596974B (zh) 2011-04-15 2016-08-31 卡姆普根有限公司 多肽和多核苷酸及其用于治疗免疫相关失调和癌症的用途
MX351600B (es) 2011-06-03 2017-10-20 Xoma Technology Ltd Anticuerpo especificos para tgf-beta.
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
PT2726508T (pt) 2011-06-28 2017-09-26 Oxford Biotherapeutics Ltd Anticorpos para adp-ribosil ciclase 2
CA2836855C (en) 2011-06-30 2020-07-14 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
HUE040276T2 (hu) 2011-07-01 2019-02-28 Novartis Ag Eljárás metabolikus rendellenességek kezelésére
TW201328706A (zh) 2011-12-05 2013-07-16 Novartis Ag 表皮生長因子受體３（ｈｅｒ３）之抗體
KR20140103135A (ko) 2011-12-05 2014-08-25 노파르티스 아게 Her3의 도메인 ii에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체
WO2013093762A1 (en) 2011-12-21 2013-06-27 Novartis Ag Compositions and methods for antibodies targeting factor p
AU2013216320A1 (en) 2012-02-01 2014-04-03 Compugen Ltd. C10RF32 antibodies, and uses thereof for treatment of cancer
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
AU2013277051B2 (en) 2012-06-22 2018-06-07 King's College London Novel VISTA-Ig constructs and the use of VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
JP6368308B2 (ja) 2012-09-07 2018-08-01 トラスティーズ・オブ・ダートマス・カレッジ 癌の診断および治療のためのｖｉｓｔａ調節剤
LT2928921T (lt) 2012-12-05 2021-04-26 Novartis Ag Kompozicijos ir būdai, skirti antikūnams nukreipti į epo
UY35195A (es) 2012-12-18 2014-07-31 Novartis Ag Composiciones y metodos para proteinas de accion prolongada
ES2667333T3 (es) 2012-12-28 2018-05-10 Precision Biologics, Inc. Anticuerpos monoclonales humanizados y métodos de uso para el diagnóstico y el tratamiento del cáncer de colon y páncreas
MA38322B1 (fr) 2013-02-08 2018-09-28 Novartis Ag Anticorps anti-il-17a et leur utilisation dans le traitement de troubles auto-immuns et inflammatoires
CN105246916A (zh) 2013-03-14 2016-01-13 诺华股份有限公司 针对notch 3的抗体
US9562101B2 (en) 2013-06-21 2017-02-07 Novartis Ag Lectin-like oxidized LDL receptor 1 antibodies and methods of use
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
TW201536318A (zh) 2013-08-14 2015-10-01 Novartis Ag 治療偶發性包涵體肌炎之方法
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
PL3712174T3 (pl) 2013-12-24 2022-07-04 Janssen Pharmaceutica Nv Przeciwciała i fragmenty anty-vista
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
EA037006B1 (ru) 2014-06-06 2021-01-26 Бристол-Майерс Сквибб Компани Антитела к индуцируемому глюкокортикоидами рецептору фактора некроза опухолей (gitr) и их применения
CN107073109B (zh) 2014-06-11 2021-08-06 凯西·A·格林 Vista激动剂和拮抗剂抑制或增强体液免疫的用途
WO2015198240A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
US20170291939A1 (en) 2014-06-25 2017-10-12 Novartis Ag Antibodies specific for il-17a fused to hyaluronan binding peptide tags
US20170290876A1 (en) 2014-06-25 2017-10-12 Novartis Ag Compositions and methods for long acting proteins
EP3194437B1 (en) 2014-08-07 2021-01-20 Novartis AG Angiopoietin-like 4 (angptl4) antibodies and methods of use
TN2017000019A1 (en) 2014-08-07 2018-07-04 Novartis Ag Angiopoietin-like 4 antibodies and methods of use.
DK3221363T3 (da) 2014-11-21 2020-08-10 Bristol Myers Squibb Co Antistoffer mod cd73 og anvendelser deraf
MX2017007136A (es) 2014-12-05 2017-12-04 Immunext Inc Identificacion de vsig8 como el receptor vista putativo y su uso para producir moduladores vista/vsig8.
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
BR112017025191A2 (pt) 2015-05-29 2018-07-31 Bristol-Myers Squibb Company anticorpos contra ox40 e uso dos mesmos
CA2982237A1 (en) 2015-06-05 2016-12-08 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
DK3313882T3 (da) 2015-06-24 2020-05-11 Janssen Pharmaceutica Nv Anti-VISTA antistoffer og fragmenter
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
EP3331914A1 (en) 2015-08-03 2018-06-13 Novartis AG Methods of treating fgf21-associated disorders
JP6516925B2 (ja) 2015-09-09 2019-05-22 ノバルティス アーゲー 胸腺間質性リンパ球新生因子（ｔｓｌｐ）結合性抗体および抗体を使用する方法
US10000561B2 (en) 2015-09-09 2018-06-19 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules
MX2018006072A (es) 2015-11-19 2018-08-01 Squibb Bristol Myers Co Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
EP3389711A1 (en) 2015-12-18 2018-10-24 Novartis AG Antibodies targeting cd32b and methods of use thereof
MX2018009800A (es) 2016-02-12 2018-11-09 Janssen Pharmaceutica Nv Anticuerpos y fragmentos anti-vista, usos de los mismos y procedimientos de identificacion de los mismos.
EA201891983A8 (ru) 2016-03-04 2020-05-28 Бристол-Майерс Сквибб Компани Комбинированная терапия антителами к cd73
JP7277047B2 (ja) 2016-04-15 2023-05-18 イミュネクスト インコーポレイテッド 抗ヒトｖｉｓｔａ抗体およびその使用
JP7138567B2 (ja) 2016-04-27 2022-09-16 ノバルティス アーゲー 成長分化因子１５に対する抗体およびそれらの使用
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
JP7231411B2 (ja) 2016-06-15 2023-03-01 ノバルティス アーゲー 骨形成タンパク質６（ｂｍｐ６）の阻害剤を使用して疾患を処置する方法
CN109757103B (zh) 2016-07-14 2024-01-02 百时美施贵宝公司 针对tim3的抗体及其用途
CA3032146A1 (en) 2016-08-03 2018-02-08 Bio-Techne Corporation Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy
JP7045724B2 (ja) 2016-11-07 2022-04-01 ニューラクル サイエンス カンパニー リミテッド 配列類似性を持つ抗ファミリー１９、メンバーａ５抗体及びその用途
JP2020500020A (ja) 2016-11-14 2020-01-09 ノバルティス アーゲー 融合誘導性タンパク質ｍｉｎｉｏｎに関連する組成物、方法、および治療上の使用
KR102616666B1 (ko) 2016-12-23 2023-12-27 노파르티스 아게 인자 xi 항체 및 사용 방법
MX2019007924A (es) 2016-12-28 2020-01-27 Invvax Inc Vacunas contra la influenza.
FI3580237T3 (fi) 2017-02-08 2025-07-21 Novartis Ag FGF21-mimeettivasta-aineita ja niiden käyttöjä
CN110461359B (zh) 2017-03-24 2025-01-21 诺华股份有限公司 用于预防和治疗心脏病的方法
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
CN110785433A (zh) 2017-06-28 2020-02-11 诺华股份有限公司 预防和治疗尿失禁的方法
EP3700933A1 (en) 2017-10-25 2020-09-02 Novartis AG Antibodies targeting cd32b and methods of use thereof
AU2018372135A1 (en) 2017-11-22 2020-05-28 Novartis Ag Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
US12129297B2 (en) 2018-01-12 2024-10-29 Bristol-Myers Squibb Company Antibodies against TIM3 and uses thereof
US11787857B2 (en) 2018-02-02 2023-10-17 Bio-Techne Corporation Compounds that modulate the interaction of VISTA and VSIG3 and methods of making and using
AU2019236865A1 (en) 2018-03-23 2020-10-01 Bristol-Myers Squibb Company Antibodies against MICA and/or MICB and uses thereof
TW202513581A (zh) 2018-03-28 2025-04-01 美商必治妥美雅史谷比公司 介白素-2/介白素-2受體阿法融合蛋白及其使用方法
CN119569873A (zh) 2018-05-10 2025-03-07 纽洛可科学有限公司 抗序列相似家族19成员a5的抗体及其使用方法
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
JP2022514837A (ja) 2018-12-18 2022-02-16 ノバルティス アーゲー 抗第ＸＩ／ＸＩａ因子抗体に対する反転結合剤及びそれらの使用
CN113412281B (zh) 2018-12-26 2024-07-23 感应检查疗法公司 Btn3a结合蛋白及其用途
MX2021008796A (es) 2019-01-22 2021-11-12 Bristol Myers Squibb Co Anticuerpos contra subunidad alfa il-7r y usos de estos.
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
EP4182025A1 (en) 2020-07-16 2023-05-24 Novartis AG Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
US12018254B2 (en) * 2020-07-27 2024-06-25 Wisconsin Alumni Research Foundation Methods of making unbiased phage libraries
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
WO2023217743A1 (en) 2022-05-10 2023-11-16 Imcheck Therapeutics Anti-btn3a antibodies for use in methods of treating gastro-intestinal inflammatory disorders
WO2025155877A2 (en) 2024-01-18 2025-07-24 The Regents Of The University Of California Antibodies binding to pad4 and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991015581A1 (en) * 1990-04-05 1991-10-17 Roberto Crea Walk-through mutagenesis
WO1998027230A1 (en) * 1996-12-18 1998-06-25 Maxygen, Inc. Methods and compositions for polypeptide engineering
WO2000018906A2 (en) * 1998-09-29 2000-04-06 Maxygen, Inc. Shuffling of codon altered genes
WO2000053744A2 (en) * 1999-03-09 2000-09-14 Diversa Corporation End selection in directed evolution

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6238884B1 (en) * 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991015581A1 (en) * 1990-04-05 1991-10-17 Roberto Crea Walk-through mutagenesis
WO1998027230A1 (en) * 1996-12-18 1998-06-25 Maxygen, Inc. Methods and compositions for polypeptide engineering
WO2000018906A2 (en) * 1998-09-29 2000-04-06 Maxygen, Inc. Shuffling of codon altered genes
WO2000053744A2 (en) * 1999-03-09 2000-09-14 Diversa Corporation End selection in directed evolution

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HORWITZ B H ET AL: "SATURATION MUTAGENESIS USING MIXED OLIGONUCLEOTIDES AND M13 TEMPLATES CONTAINING URACIL", METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC, SAN DIEGO, CA, US, vol. 185, 1990, pages 599 - 611, XP000993477, ISSN: 0076-6879 *
SCHULTZ S ET AL: "Site-saturation studies of beta-lactamase: production and characterization of mutant beta-lactamases with all possible amino acid substitutions at residue 71", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 83, no. 6, March 1986 (1986-03-01), pages 1588 - 1592, XP002147196, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2002092780A3 (en) 2004-03-25
JP2004532038A (ja) 2004-10-21
WO2002092780A2 (en) 2002-11-21
EP1421203A2 (en) 2004-05-26

Similar Documents

Publication Publication Date Title
EP1421203A4 (en) NEW ANTIGEN-BINDING MOLECULES FOR THERAPEUTIC, DIAGNOSTIC, PROPHYLACTIC, ENZYMATIC, INDUSTRIAL AND AGRICULTURAL APPLICATIONS AND METHOD FOR THE PRODUCTION AND SCREENING THEREOF
IL172871A0 (en) Rg1 antibodies and uses thereof
AU2003222142A1 (en) Micro/nano-embossing process and useful applications thereof
MXPA03007197A (es) Moleculas de enlace terapeuticas.
EP1583428A4 (en) TREATMENT OF DAIRY PROTEINS AND CORRESPONDING APPLICATIONS
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
AU2002258388A1 (en) Narc8 programmed cell-death-associated molecules and uses thereof
AU2002359495A1 (en) Anti-tnf antibodies, compositions, methods and uses
AU2003225976A1 (en) Anti-tnf antibodies, compositions, methods and uses
AU2001275990A1 (en) 16816 and 16839, novel human phospholipase c molecules and uses therefor
AUPR535101A0 (en) Novel therapeutic molecules
AU2002327945A1 (en) Human delta-n p73 molecules and uses thereof
AU2002334781A1 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
EP1582589A4 (en) PROTEIN COMPLEX, METHOD FOR THE PRODUCTION AND USE THEREOF
GB0115780D0 (en) Therapeutic molecules and uses thereof
AU2002953223A0 (en) Novel therapeutic molecules and uses thereof
WO2003023002A9 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
AU2002303232A1 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
AU2002337248A1 (en) Nucleic acids coding for novel fbox proteins, their diagnostic and therapeutic uses
AU2002302191A1 (en) Socs-5 molecules, screening therefore and therapeutic uses thereof
AU2002322404A1 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
AU2002254163A1 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
AU2001294181A1 (en) Novel protein, process for producing the same and use thereof
AU2002356472A1 (en) Dairy process and product
AUPR713201A0 (en) Novel therapeutic molecules and uses therefor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031212

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050415

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12Q 1/68 B

Ipc: 7C 12N 15/66 B

Ipc: 7C 12N 15/10 A

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060912